LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME: HOW TO CHOOSE THE PATIENT?
The review tells about challenges of antithrombotic therapy in patients after acute coronary syndrome. The efficacy and safety of long-term administration of anticoagulants (warfarin as well as novel anticoagulants), in addition to standard antiplatelet therapy, is discussed. The focus is on rivar...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
«REMEDIUM GROUP» Ltd.,
2016-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The review tells about challenges of antithrombotic therapy in patients after acute coronary syndrome. The efficacy and safety of long-term administration of anticoagulants (warfarin as well as novel anticoagulants), in addition to standard antiplatelet therapy, is discussed. The focus is on rivaroxaban, low doses of which are officially indicated for the prevention of cardiovascular death and myocardial infarction in patients after acute coronary syndrome occurring with increased values of myocardial injury markers. Clinical characteristics of patients feasible for this treatment approach are considered. |
|---|---|
| Item Description: | 2307-1109 2658-5952 10.21518/2307-1109-2016-1-26-38 |